+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Completed

Age: 13Years +
All Genders
ID00000905

Discontinuation of Maintenance Therapy for Cytomegalovirus CMV Retinitis After Immune Reconstitution by Potent Antiretroviral Therapy Safety, Virology, and Immunology Profiles

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2008-07-30

75

Participants Needed

25

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

The purpose of this study is to see if it is safe to stop maintenance therapy in HIV-positive patients with treated and healed CMV retinitis (eye disease) who have responded well to anti-HIV (antiretroviral) therapy. The current therapies available to treat CMV retinitis are long-term therapies. However, it may be safe to stop long-term anti-CMV therapy in patients with healed CMV retinitis and stable CD4 counts resulting from taking a combination of at least 2 antiretroviral drugs.

CONDITIONS

Brief Title

A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here